Amgen (AMGN) 8-K 4 Mar 21 Amgen to Acquire Five Prime Therapeutics for Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide Financial data

Document and Entity Information

Document and Entity Information	Mar. 04, 2021
Entity Information [Line Items]
Document Type	8-K
Document Period End Date	Mar. 4, 2021
Entity Registrant Name	Amgen Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-37702
Entity Tax Identification Number	95-3540776
Entity Address, Address Line One	One Amgen Center Drive
Entity Address, City or Town	Thousand Oaks
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91320-1799
City Area Code	805
Local Phone Number	447-1000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	true
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Entity Central Index Key	0000318154
Amendment Flag	false
Common Stock [Member]
Entity Information [Line Items]
Title of 12(b) Security	Common Stock $0.0001 par value
Trading Symbol	AMGN
Security Exchange Name	NASDAQ
1.250% Senior Notes Due 2022 [Member]
Entity Information [Line Items]
Title of 12(b) Security	1.250% Senior Notes Due 2022
Trading Symbol	AMGN22
Security Exchange Name	NASDAQ
2.00% Senior Notes Due 2026 [Member]
Entity Information [Line Items]
Title of 12(b) Security	2.000% Senior Notes Due 2026
Trading Symbol	AMGN26
Security Exchange Name	NASDAQ